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ABSTRACT
Diseases and conditions affecting the lower urinary tract are a leading cause of dysfunctional sexual
health, incontinence, infection and kidney failure.  The growth, differentiation, and repair of the
bladder’s epithelial lining is regulated by fibroblast growth factor (FGF)-7 and -10 via a paracrine
cascade originating in the mesenchyme (lamina propria) and targeting the receptor for FGF-7 and -
10 within the transitional epithelium (urothelium).  Recombinant FGF- 7 and -10 induce
proliferation of human urothelial cells in vitro and transitional epithelium of wild-type and FGF7-
null mice in vivo. To determine the extent that induction of urothelial cell proliferation during the
bladder response to injury is dependent on FGF-7, an animal model of partial bladder outlet
obstruction was developed. Unbiased stereology was used to measure the percentage of
proliferating urothelial cells between obstructed groups of wild-type and FGF7-null mice. The
stereological analysis indicated that a statistical significant difference did not exist between the two
groups, suggesting that FGF-7 is not essential for urothelial cell proliferation in response partial
outlet obstruction. In contrast, a significant increase in FGF-10 expression was observed in the
obstructed FGF-7 null group, indicating that the compensatory pathway that functions in this model
result in urothelial repair.
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INTRODUCTION
Bladder outlet obstruction is a medical condition that can affect men, women and children.
Lower urinary tract obstruction can lead to voiding dysfunction as well as kidney failure.  Many
men suffer from obstruction due to benign prostatic hypertrophy, leading to both medical and
psychosocial dysfunction (2).  Associated with these dysfunctions are severe losses of smooth
muscle function and bladder contractility, or progression of the bladder towards conditions of severe
hypertrophy and hypercontraction (3).  Incomplete bladder emptying in patients is also a risk for
urinary tract infection.  In addition, children born with congenital forms of bladder outlet
obstruction such as posterior urethral valves or children born with functional bladder obstruction,
such as in spina bifida patients, can lead to significant urinary incontinence and renal dysfunction.
Transitional epithelium that lines the urinary tract exhibits one of the slowest turnover rates
among mammalian epithelia, estimated at once every 365 days (4-7). Although the urothelial cells
that comprise this epithelia rest in G0 during normal conditions, they remain active in metabolic
processes that accompany shape change during bladder emptying and filling.  In response to injury,
transitional epithelium exhibits a remarkable ability to turnover within 24-48 hours after the initial
insult. The identity of the mitogenic signal that gives rise to basal urothelial cell proliferation has
been attributable to growth factors. Such factors are classified as either paracrine, autocrine, or
juxtacrine, depending on the originating and target cell type. Mitogens known to act on human
urothelial cells include epidermal growth factor (8), heparin-binding epidermal growth factor-like
growth factor (9), activators of the estrogen receptor (10, 11), transforming growth factor-α (12),
fibroblast growth factor-1 (12), and fibroblast growth factor-10 (13).
The model most frequently used to study the urothelial response to injury is partial outlet
obstruction of the bladder via urethral ligation (14).  The wound healing response appears to be
constant from animal model to animal model and mimics the clinical response seen in humans (15-
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17). Such events include urothelial cell proliferation within 24-48 hr, subsequent hypertrophy of the
bladder wall, and alterations in detrusor muscle and the extracellular matrix.  Experimental animal
models have been exploited to study bladder dysfunctions that are similar to those observed in men
with benign prostatic hyperplasia (18, 19). Furthermore, this experimental model has direct
implications for other clinical disease states such as congenital (i.e. posterior urethral valves) or
acquired (urethral stricture or bladder neck contraction) urinary tract obstruction.
Fibroblast growth factor-7 (FGF-7) is a 194 aa polypeptide implicated in both the induction of
basal urothelial cell proliferation and the expansion of transitional epithelium (14, 20). Also known
as keratinocyte growth factor (21, 22), FGF-7 is one of 24 members of the FGF family of
polypeptide growth factors. The crystal structure of FGF-7 has been solved (1, 23). The protein
folds into a beta-trifoil motif similar to other members of the FGF family whose structures have
been solved. Although FGFs 11-14 exhibit striking structural similarities to FGF-10, FGFs 11-14
have diverged to direct related surfaces towards interaction with protein targets distinct from
canonical FGF receptors (FGFR) (24).
FGF-7 and FGF-10 are considered to be paracrine factors, originating in mesenchyme but active
only upon epithelium (13, 21, 22, 25). The formation of a specific FGF7-containing FGFR signal
transduction complex requires 3 components: the FGF-7 polypeptide, proteoglycans that contain
either heparan- (26, 27), dermatin- (28), or chondroitin- (29) sulfate, and an alternatively-spliced
tyrosine kinase protein product of the FGFR2 gene (7, 30), and (27). This receptor, known as the
keratinocyte growth factor receptor (KGFR), the FGFR2IIIb splice variant, or the FGFR2 isoform 2
splice variant, is a cell-surface transmembrane protein that undergoes dimerization upon ligand
binding and subsequent autophosphorylation of intracellular tyrosine residues (31). Allelic
mutations in the FGFR2 exons that encode the isoform 2 splice variant are known to give rise to a
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number birth defects that include craniosynostosis syndromes (32).  It is believed that the FGFR2
isoform 2 splice variant serves as a receptor for both FGF-7 and FGF-10.
Mice that contain a targeted disruption of the FGF-7 gene exhibit defects in (i) cells that give
rise to the hair shaft (33), (ii) ureteric bud outgrowth (34), and (iii) stratification of bladder
urothelium (35). The collective evidence demonstrates an essential role for FGF-7 in development,
growth, differentiation, and homeostasis of the mucosal lining of the urinary tract. In contrast to the
FGF-7 null mouse, the FGF-10 null mouse lacks limb bud initiation and lung development (36).  In
addition, the FGF-10 null mouse exhibits gross anatomical defects in the urinary tract with
includinga urothelium that fails to stratify (37). Consequently, FGF-10 null mice die at birth,
precluding their use in experimental models of partial bladder obstruction.
 This study demonstrated the mitogenic potential of FGF-7 on human and murine urothelial
cells. The growth factor was found to stimulate resting cells to exit from G0 and traverse the cell
cycle. To determine if the mitogen was responsible for the induction of urothelial cell proliferation
during the initial response of the bladder to injury, we examined whether there was a difference in
the urothelial response to injury between wild-type and FGF7-null mice in a model of partial outlet
obstruction. Stereological analysis of obstructed bladders revealed that a statistically significant
difference did not exist indicating that FGF-7 is not essential for urothelial cell proliferation during
the response to partial outlet obstruction of the urinary bladder.  Further stereological analysis
revealed a significant fold increase of FGF-10 synthesis in obstructed FGF7-null mice via a
compensatory paracrine mechanism.
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RESULTS
Isolation and Sequence Analysis of FGF-7 cDNA from Human Urinary Bladder
A 0.492 kbp partial cDNA fragment encoding FGF-7 from a human urinary bladder cDNA library
by reverse transcription and PCR was cloned, sequenced, and found to be 100% identical with the
corresponding region present in the NCBI reference sequence encoding human lung FGF-7 mRNA
(Accession NM_002009.2). Analysis of the 0.492 kbp bladder FGF-7 sequence predicted an open
reading frame for a polypeptide exhibiting a length of 164 residues, a Mr of 18,594.70, a pI of 9.82,
and a molar extinction coefficient of 21,770 mol g-1 cm-1. These data are consistent with the
deduced primary structure being the mature, secreted form of bladder FGF-7.
Distribution and Characterization of FGF-7 Sequences in the Human Genome
The distribution of the bladder FGF-7 cDNA sequence in the human genome is shown in Table
1. Regions of identity or near-identity were localized to chromosomes 9, 15, 18, and 21. Because
our bladder FGF-7 cDNA sequence does not contain 5’- and 3’- mRNA sequences, we performed
an analogous search with the reference sequence assigned to the FGF-7 mRNA by the National
Center for Biotechnology Information. In Table 1, the bracketed row of data represents additional
genomic regions detected with the full-length 3,853 base mRNA reference sequence. Five, four, two
and two regions of identity or near-identity were localized to chromosomes 9, 15, 18, and 21,
respectively.
Of the 4 chromosomes identified to contain FGF-7 sequences, we were able to localize the gene
that encodes FGF-7 to chromosome 15. The structure of the gene was deduced from the 18,451.822
kbp chromosome 15 reference genomic contig (NCBI Accession NT_010194.13). The fibroblast
growth factor 7 gene is characterized by a length of at least 64.065 kbp, a presence on both
chromatids of chromosome 15, a cytogenetic localization of 15q15-q21.1 at 41.2 +/- 13.3 MB, and
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4 exons that generate a 3,852 kb mRNA. The arrangement of introns and exons is displayed in
Table 2. Exons 2 and 3 are separated by an unusually large intron (58.567 kbp) that also splits the
codon for Asn67  (underlined and bold type in Table 2). Fifty-seven single nucleotide
polymorphisms (SNP) for this gene are present in NCBI’s public SNP database (Human Genome
Build 31, February 28, 2003).
The extent to which introns 2 and 3, and exons 3 and 4, of the chromosome 15 FGF-7 were
distributed among chromosomes 9, 18, and 21 was also investigated (Table 3). The size of exons 3
and 4 were each almost perfectly conserved among chromosomes 18, 21, one region located in the
middle of the p arm (Chr 9pm), and two regions proximal to the centromere (Chr 9qc) and telomere
(Chr 9qt) of the q arm of chromosome 9. The length of the chromosome 18 FGF-7 sequence is
nearly identical to the length of the chromosome 15 FGF-7 gene sequence. Scattered over these 3
chromosomes are 7 regions that exhibit near-identical sequences. We considered these regions to be
duplications of the FGF-7 gene sequences present on chromosome 15. These duplicated copies
contain only portions of the FGF-7 gene sequence (Figure 1). Such duplications for the FGF-7 gene
have been previously detected by Southern blotting (38) and by fluorescence in situ hybridization
(39). In this latter study, the duplications were visualized on chromosomes 2, 9 (two spots), 15, 18
(two spots), and 21 (two spots). Our sequence analysis differs from these results in that no
sequences were identified to account for the chromosome 2 spot.
Five copies of the duplicated sequences were localized to chromosome 9 (Table 3 and Figure 1).
Among the conserved copies, two gap-containing sequences were identified proximal to the
centromere on the 9p arm (9pc) and proximal to the telomere on the 9q arm (9pt).
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Analysis of Human Urinary Bladder FGF-7 Amino Acid Sequence
Figure 2 displays the deduced amino acid sequence for the 173 aa recombinant rFGF7-His
protein. The N-terminus was engineered to contain a Met residue to provide a codon for initiation of
translation in E. coli. The C-terminus was engineered to contain a His-hexamer to provide for
detection during biological assays and for isolation of the recombinant protein by metal-chelate
affinity chromatography. The calculated Mr and isoelectric point of rFGF7-His is 20,151 and 9.58,
respectively.
Motifs and sites for post-translational modification that are predicted to occur in the wild-type
FGF-7 sequence are also shown in Figure 2. Naturally occurring FGF-7 proteins are predicted to
contain sites for N-linked glycosylation (Asn16), casein kinase II phosphorylation site (Ser18 and
Thr150), phosphorylation site by protein kinase C (Ser124) and amidation (Gly147). A 24 aa region
(Gly96-Tyr119) is the consensus sequence for the FGF family of heparin-binding polypeptides (40)
and a potential transmembrane segment (41). The “glycine box” sequence (NQKGIPVRG, residues
139 – 147) (42) is the major determinant for the specificity of the binding of FGF-7 to heparan
sulfate-FGFR complexes (40). Residues that have been implicated in binding to heparin (23) (1)
were identified as Arg43, Asn117, Asn139, Gln140, Val145,Lys148, Asn154, Lys155, and Thr156
(Figure 2). These residues form a positively charged motif that is present on the surface of the
macromolecule (Supplemental Figure 2). The heparin-binding motif of rFGF7-His is therefore
exposed to the solvent, and, more importantly, available to bind to and interact with heparan-,
chondroitin-, or dermatin- sulfate proteoglycans.
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Expression, Isolation, and Characterization of Recombinant FGF-7 in Escherichia coli
The expression of recombinant FGF-7 was realized as a fusion protein with a hexamer of His
residues at the C-terminus (Figure 2 and Supplemental Figure 2). This recombinant fusion protein,
designated rFGF7-His, was found to comprise 1-2% of the total cellular protein and to partition
equally between the soluble and insoluble fractions of lysed BL21trxB(DE3) E. coli (data not
shown). We pursued the characterization of the soluble form of rFGF7-His with respect to 1)
intactness, 2) ability to interact with heparin, 3) folding, and 4) biological activity in vitro.
rFGF7-His was determined to be full-length because a) amino acid sequencing of the N-
terminus (ACNDMTPEQMATNV) of the isolated protein was found to be consistent with the N-
terminus of the mature form of the NCBI reference sequence NM_002009.2 and b) the C-terminal
His hexamer conferred the ability of rFGF7-His to bind avidly to nickel-chelate affinity resins
(Figure 3, lane 1).
rFGF7-His was judged to be folded properly because a) it partitioned into the soluble phase of
the bacterial extract, b) the isolated, non-reduced form exhibited a greater mobility on SDS-PAGE
than the isolated, reduced form (data not shown) and c) it bound to heparin (Figure 3, lane 2).
Soluble rFGF7-His was isolated as a monomeric polypeptide of ~24 kDa by nickel-chelate (Figure
3, lane 1) and heparin affinity chromatographies (Figure 3, lane 2). The ability of soluble rFGF7-
His to interact with nickel-chelate resins through its C-terminal His-hexamer (Figure 3, lane 1)
demonstrates that this His- hexamer is localized to the periphery of the folded protein, in agreement
with the crystal structure of the human (23) and rat (1) FGF-7 proteins. Concerns that manipulation
of the C-terminal region of rFGF7-His would influence its folding and biological activity (43)
prompted us to ask if our preparations of rFGF7-His would bind to heparin-affinity resins in the
same manner as reported in the literature. Figure 3 (lane 2) demonstrates that rFGF7-His elutes
from heparin-affinity chromatography columns at 1.0 M LiCl, an ionic strength in agreement with
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that reported for native (21) or rFGF-7 (44). Sequential chromatography on heparin-affinity
followed by nickel-chelate affinity chromatographies (Figure 3, lane 3), or the converse (nickel-
chelate followed by heparin, Figure 3, lane 4) clearly demonstrate that the presence of the C-
terminal His-hexamer does not impact the ability of the recombinant protein to interact with heparin
or fold into a conformationally stable state. Stabilization of rFGF7-His was found to be enhanced by
inclusion of heparin in the storage buffer solution (not shown).
Biological Activities of Recombinant FGF-7
rFGF7-His was found to exhibit mitogenic activity on human urothelial cells in vitro (Figure 4).
Cultures of urothelial cells that attained confluence by incubation in growth media reduced the rate
of [3H]-thymidine incorporation from 37,600 ± 900 cpm to 6,000 ± 360 cpm after switching to
starvation medium (Figure 4B). Addition of increasing concentrations of rFGF7-His to cells in
starvation medium resulted in a dose-dependent increase of incorporation of [
3H]-thymidine into
urothelial cell DNA. A 5.6-fold increase in incorporation was observed at a concentration of 0.1 ng
ml-1, relative to no input growth factor. The mitogenic activity of rFGF7-His was dependent on the
absence of input heparin. This activity was observed only with confluent cultures, whereas non-
confluent cultures resulted in non-significant levels of incorporation (data not shown). The culture in
Figure 4A was confluent and displayed the typical cobblestone appearance of urothelial cells in vitro, as
compared to published photographs (8). Atop Figure 4A is a “giant” cell with two prominent nuclei – this
urothelial cell-subtype corresponds to the large, polygonal suprabasal cell that comprise the lumenal layer
of transitional epithelium. Suprabasal urothelial cells are the largest epithelial cells in mammals.
Secretory granules, lipid inclusions, and lysosomes are prominent in these suprabasal cells, which are
also positive for uroplakin (data not shown).
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rFGF-7 (Palifermin) was also found to exhibit mitogenic activity on the urothelial cells of
murine transitional epithelium (Figure 5). For these experiments, 100 µg of rFGF-7 (Palifermin) in
vehicle was injected each day for 14 days into the neck folds of C57BL/6J mice. Subsequent
histological staining with Mason’s trichrome (data not shown) revealed that animals treated with
rFGF-7 (Palifermin) underwent a dramatic expansion of the number of urothelial cell layers of
urinary bladder transitional epithelium (data not shown). A layer of stratified urothelium 15-25 cells
thick characterized this expansion. In contrast, control mice that received vehicle only did not
exhibit detectable urothelial expansion, but instead displayed a normal layer of 2-5 cells thick (data
not shown).
Immunostaining with antibodies specific for the nuclear protein Ki-67, an established marker of
epithelial cell proliferation (45, 46), demonstrated that basal urothelial cells were traversing the cell
cycle (Figure 5). The Ki-67 signal persisted throughout the period of rFGF-7 (Palifermin)
administration and was prevalent in all animals tested (n = 3). A Ki-67 signal was observed to
decrease in intensity as cells detached from the urothelial basement membrane and migrated
towards the bladder lumen. Animals receiving vehicle did not exhibit Ki-67 immunoreactivity. The
positive correlation between rFGF-7 (Palifermin) administration, expansion of the layers of
transitional epithelium, and Ki-67 immunoreactivity confirms that FGF-7 is a positive regulator of
urothelial cell proliferation.
FGF-7 is a Non-Essential Mitogen During Partial Bladder Outlet Obstruction
An experimental mouse model of partial bladder outlet obstruction was developed wherein a
partial surgical ligature was placed around the urinary bladder outlet. In this model, animals that
underwent partial ligation exhibited bladders that were abnormally distended. The hallmark feature
of transitional epithelium over the 8 days of obstruction was the marked increase of stratification of
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transitional epithelium and of urothelial cells traversing the cell cycle. The mitogenic signal that
stimulated the exit of these cells from the GO phase and the progression through the cell cycle was
hypothesized to originate in the mesenchyme, and that this principal mesenchymal factor was FGF-
7.
To test our hypothesis, a comparison of the urothelial response to obstruction between wild-type
and FGF-7 null mice was performed. It was assumed that this response would involve individual
urothelial cells undergoing proliferation. Accordingly, urothelial cells traversing the cell cycle were
detected by immunostaining with polyclonal antibodies specific to the Ki-67 nuclear antigen, an
accepted marker of proliferating epithelial cells.
Quantification of total and proliferating urothelial cells was achieved by analysis using the
principles of unbiased stereology. If mesenchymal FGF-7, produced and secreted by fibroblasts of
the lamina propria, was the principal mitogen that stimulated the proliferation of urothelial cells,
then lack of this major paracrine factor in FGF7-null mice should influence the urothelial response
to injury by exhibiting a measurable decrease in the percentage of proliferating urothelial cells, as
compared to wild-type mice.
The following transitional epithelia exhibited 2-5 layers of urothelial cells that typify the normal
phenotype and were non-reactive with antibodies specific for the Ki-67 antigen: wild-type normal,
FGF7-null normal, wild-type sham, and FGF7-null sham (data not shown). These results indicate
that urothelial cells were not removed from the G0 resting phase of the cell cycle by surgical
procedures that did not include urethral ligation.
Mice that underwent ligation for 1-2 days exhibited minimally detectable urothelial expansion
(data not shown). Ligation for 4 days elicited subtle, but detectable, urothelial expansion (data not
shown). The most consistent and reproducible efforts required 8 days of partial obstruction.
Partially obstructed bladders after 8-days post-ligation were prominently larger and distended than
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control animals (data not shown), a result that indicated that partial outlet obstruction of the bladder
was successfully accomplished by ligation of the urethra.
In contrast to control and sham-operated animals, transitional epithelia from animals that
underwent partial urethral ligation at the bladder neck exhibited marked immunoreactivity with
antibodies specific for the Ki-67 nuclear antigen. The total number of Ki-67 positive cells, as well
as the total number of urothelial cells, was determined by stereology (Figure 6). Calculation of
mean values is presented in Table 4. The percentage of Ki-67 positive cells for obstructed wild-type
and FGF7-null mice was calculated to be 1.78 ± 0.46 cells and 1.60 ± 0.94, respectively. A
statistical comparison between these two groups with the student’s t-test indicated that this
difference was not significant.
FGF-10 is a Compensatory Mitogen During Partial Bladder Outlet Obstruction
Bladder specimens from mice subjected to partial outlet obstruction as described above were
tested for FGF-10 expression.  FGF7- null and WT mice were compared for differential FGF-10
expression among fibroblasts within the lamina propria using the same stereologic analysis as
described above.  The mean number of FGF-10 positively stained fibroblasts for the WT and the
FGF7-null mice per bladder were 195 and 1086, respectively (Table 4).  This difference was
statistically significant (p = 0.004) proving that FGF-10 expression was up-regulated in response to
obstruction.  The collective data support the hypothesis that FGF-10 is an essential and
compensatory mitogen for murine urothelium turnover.
DISCUSSION
In animal models, partial outlet obstruction of the urinary bladder induced by urethral ligation elicits
a 3-phase programmed response: (i) an initial hypertrophy phase, (ii) a compensatory phase, and
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(iii) a decompensatory phase (18, 47). The early molecular response of the lamina propria and
urothelium in response to outlet obstruction has been studied in the context of mesenchymal-
epithelial interactions, specifically the role of mesenchymal growth factors in the induction of
urothelial cell proliferation (13, 15, 48-50). In these models, FGF-7 mRNA has consistently been
observed to be markedly upregulated in response to obstruction (14, 15, 47). Our analysis of the
FGF-7 gene indicated that while exons 3 and 4 were duplicated within the human genome, we
found no evidence that full-length FGF-7 mRNAs could arise from any other locus than 15q15-
q21.1.
Mesenchymal mediators of epithelial cell behavior, proliferation, and differentiation represent
an important means of regulating development, homoeostasis, and the response to injury. In the
urinary bladder, the paracrine mediator that has been most studied is FGF-7, a polypeptide
synthesized and secreted by fibroblasts of the lamina propria (15, 20, 47-50). Our study
demonstrates that this growth factor is a mitogen for human and murine urothelial cells of
transitional epithelium, a result in agreement with prior reports that studied the effect of the purified
factor on transitional epithelia from monkey (51), rat (51, 52), and murine (20, 35)  sources.
Equivalent biological activities were observed for rFGF7-His (our preparations) and rFGF-7
(provided by Amgen as the pharmaceutical Palifermin) in assays that monitored the incorporation of
[3H]-thymidine into the DNA of human urothelial cells in vitro. The mitogenic activity of rFGF7-
His on human urothelial cells was observed only with confluent cultures, a phenomenon previously
reported for normal human keratinocytes (53). Our data is also in agreement with prior reports (44,
54) that demonstrated that heparin was inhibitory to the stimulatory activity of rFGF-7 on Balb/MK
keratinocytes.
Since the initial response of the bladder to outlet obstruction is to turnover its urothelium via
reciprocal mesenchymal-epithelial interactions (14, 15, 47), we asked to what extent
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mesenchymally-derived FGF-7 regulates urothelial cell proliferation in response to obstruction. To
answer this question, we quantified the proliferative response to obstruction by stereological
analysis of Ki-67 staining of the urothelium. Not only were the total number of Ki-67 positive cells
nearly equivalent between the wild-type and FGF7-null sets of mice, but the percentage of
urothelial cells traversing the cell cycle between these two sets was statistically insignificant. We
noted that the urothelial response to obstruction was variable from animal to animal, an observation
shared by other laboratories (15, 16, 55-57) and noted clinically as well.
The collective data prove our hypothesis that redundant mechanisms compensate for the lack of
FGF-7 in FGF7-null mice that continue to exhibit proliferating urothelial cells in response to
obstruction. The principal mitogenic candidate to compensate for the absence of FGF-7 was shown
to be FGF-10, a known mitogen for urothelial cells in vitro and in vivo (13, 25). Since both FGF-7
and FGF-10 can bind to, interact with, and stimulate a mitogenic signaling pathway through the
same FGFR2 isoform 2 receptor (58), we conclude that FGFR2 isoform 2 remains functional in
FGF7-null mice.
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Our prior report that the FGFR2 isoform 2 receptor is expressed by the superficial layer of transitional
epithelia (25) is clinically significant because intravesical instillation of recombinant FGF-7 and -10 into the
bladder lumen is predicted to trigger urothelial repair in response to injury due to obstruction.  In addition,
clinical conditions involving the urinary tract which cause epithelial damage such as infections and trauma
leading to stricture disease, erosive disorders such as interstitial cystitis, and urinary tract disruption from
transurethral resection surgery could be treated with mitogenic stimulation.  Ongoing work is expected to
lead to a better understanding of the steady-state interrelationships that involve urothelial cells, growth
factors, matricellular proteins, the extracellular matrix, and the urothelial basement membrane.  Advancing
the study of FGF-7 and -10 is relevant because of the polypeptides’ potential use as a clinical tool to treat,
and ultimately cure, a variety of lower urinary tract conditions and diseases.
MATERIALS AND METHODS
Materials
Human urinary bladder cDNA was obtained from Invitrogen (Carlsbad, CA). Oligonucleotide
primers were synthesized by Keystone Laboratories (Foster City, CA). Escherichia coli strains
NovaBlue and BL21trxB(DE3), Perfectly Blunt Cloning Kit, plasmid pET21d, Bug Buster lysis
reagent, and carbenicillin were purchased from Novagen (Madison, WI). Restriction enzymes NcoI
and XhoI, T4 DNA ligase, Taq polymerase, and Complete Protease Inhibitors were from Roche
Molecular Biochemicals (Indianapolis, IN). Ni-NTA metal-chelate affinity resin was from Qiagen
(Chatsworth, CA). HiTrap heparin-sepharose affinity resins were from Amersham Biochemicals
(Piscataway, NJ). SDS-PAGE gels and the Amplified Alkaline Phosphatase ImmunoBlot Assay
detection system were obtained from BioRad (Hercules, CA). Tetracycline and kanamycin were
from Calbiochem (La Jolla, CA). Recombinant FGF-7 (rFGF-7, Palifermin, rHuKGF)) was
provided by Amgen (Thousand Oaks, CA). Rabbit anti-bovine uroplakin immunoglobulins were
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obtained from Dr. H. Sun (New York University, New York, NY).  Rabbit anti-Ki67
immunoglobulins were obtained from Novocastra (Newcastle, UK).  Mouse anti-FGF10
immunoglobulins were purchased from R&D Systems (Minneapolis, MN).  Goat anti-mouse
horseradish-peroxidase conjugated immunoglobulins were obtained from Jackson ImmunoResearch
Laboratories (West Grove, PA).
Isolation of rFGF7-His
Two types of recombinant (r) FGF-7 were used in this study. rFGF7-His, prepared in our laboratory
as described in the Supplemental Materials Section and Palifermin (rFGF-7 lacking a C-terminal
His-tag), prepared and provided to us by Amgen (59).
N-terminal Amino Acid Sequencing of rFGF7-His
A 1 ml fraction eluted from a nickel-chelate affinity chromatography column that contained 25
µg ml-1 of rFGF7-His was precipitated with trichloroacetic acid, washed, dried and dissolved in
0.125 M Tris-HCl (pH 6.8), 2% (w/v) SDS, 10% glycerol, 0.05% bromphenol blue, 0.05 M
dithiothreitol. After heating to 37 °C for 20 minutes, the fraction was electrophoresed through a
15% polyacrylamide gel that contained 0.1% SDS. Thioglycolate (0.1 mM) was present in the upper
buffer chamber to scavenge unpolymerized acrylamide that could potentially result in blockage of
the N-terminus. Following electrophoresis, fractionated proteins were electrotransferred to a
polyvinylidene difluoride membrane in 0.01 M MOPS (pH 11.0) that contained 20% methanol,
visualized by staining with Coommasie Brilliant Blue R-250 and destained. The rFGF7-His band
was excised from the membrane, and sequenced by Edman degradation with an Applied Biosystems
477A protein sequencer.
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[3H]-Thymidine Incorporation Assays of Urothelial Cell Proliferation
Because of the use of human transitional epithelial tissue for this study, these experiments were
reviewed by the Institutional Review Board of Children’s Hospital and Regional Medical Center. 
Primary cultures of bladder urothelial cells derived from surgical explants were grown as
previously described (13). Assays of DNA synthesis of bladder urothelial cells were performed as
previously described (13). Incorporation of [3H]-thymidine into urothelial cell DNA as a function of
rFGF7-His was inhibited by 10 µg ml-1 heparin, in agreement with a prior report (43, 54),
presumably because of the influence of extracellular matrix components present in the cultures.
Our preparations of rFGF7-His from soluble extracts were biologically active and the
engineering of a C-terminal hexamer of histidine residues did not affect solubility, folding, or
ability to bind to heparin. However, we found that the yields of bacterial rFGF7-His were
disappointing, a result in agreement with a prior report that established that the growth factor
exhibited limited stability in aqueous media, as it undergoes denaturation followed by aggregation
at 37 °C (60). Therefore, we used Amgen’s preparations of active recombinant FGF-7 for use in
assays where milligram quantities of the growth factor were needed, e.g. injection into mice.
Induction of Murine Urothelial Cell Proliferation
rFGF-7, lacking a C-terminal histidine tag and ending at Thr165 (Figure 4), was obtained from
Amgen as the pharmaceutical Palifermin, and dissolved in vehicle (120 mM NaCl, 2.7 mM KCl, 4
mM NaH2PO4 (pH 7.4), 5 µg ml
-1 heparin) at a final growth factor concentration of 100 µg ml-1.
One ml was administered daily by intraperitoneal injection into the neck folds of wild-type
C57BL/6J mice. On day 15, mice were euthanized and their bladders were harvested en bloc by
anatomical positioning on a paraffin block. Specimens were fixed with methyl Carnoy’s solution for
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16-24 hr, transferred to 120 mM NaCl, 2.7 mM KCl, 4mM NaH2PO4 (pH 7.4), embedded in
paraffin, cut into 5-10 µm thick sections, and processed by Ki-67 immunohistochemistry (20) or
visualized with Masson’s trichrome stain.
Mouse Model of Bladder Outlet Obstruction
The Institutional Animal Care and Use Committee of Children’s Hospital and Regional Medical
Center approved these experiments. Wild-type C57BL/6J mice were obtained from B and K (Kent,
WA). FGF7-null mice (33) of the same parental inbred strain were provided by Dr. E. Fuchs (The
Rockefeller University). All mice were 8-week old females.
Two sets of mice were used:  wild-type and FGF7-null. Each set consisted of 3 groups:  (1) a
control group (n=2) that did not undergo any type of surgery; (2) a second control group (n=2) that
underwent a sham operation, i.e. abdominal cavity was opened, a 24 gauge angiocatheter was
inserted into the bladder via the urethra and then removed, and the cavity was closed; and (3) a
group (n=8) that underwent ligation at the bladder neck area. The partial ligation was performed
with mice under anesthesia. Once adequate anesthesia was obtained, the abdominal cavity was
opened, exposing the bladder and urethra.  A 26-gauge angiocatheter was inserted into the bladder
via the urethra and a 7-0-monofilament polyglyconate suture was tied around the urethra at the
bladder neck. The angiocatheter was then removed and reinserted to ensure partial outlet
obstruction was obtained. Partial outlet obstruction was confirmed by observing urine flow with
gentle extrinsic bladder compression. The abdomen was then closed, mice were allowed to recover,
and housed for 8 additional days. Mice were sacrificed; the bladder was excised, pinned to a
paraffin block, fixed in Methyl Carnoy’s solution, and sectioned according the principles of
stereology (below).
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Immunostaining with antibodies specific for Ki-67 and FGF-10
Specimens were fixed with methyl Carnoy’s solution for 16-24 hr, transferred to 120 mM NaCl, 2.7
mM KCl, 4mM NaH2PO4 (pH 7.4), embedded in paraffin, cut into 5-10 µm thick sections, and
processed by Ki-67 immunohistochemistry (20) or visualized with Masson’s trichrome stain.
Diaminobenzidine colorimetric staining with primary monoclonal mouse anti-human FGF-10 IgG
at a concentration of 15 µg ml-1 and goat anti-mouse horseradish-peroxidase conjugated IgG at
1:500 dilution was performed with 5% goat serum block.  Slides were counter-stained with a 1:10
dilution of Gill’s formula for 1 minute and fixed.
Stereology Procedures
Estimates of the number of total and proliferating (Ki-67 positive) urothelial cells, and FGF-10
positive fibroblast cells, of obstructed murine bladders were determined by use of the Optical
Fractionator (61). The Optical Fractionator method combines a 3-dimensional unbiased counting
frame (the optical disector) and an unbiased sampling method  (the fractionator) to generate
estimates of the total number of particles of interest, in this case Ki-67 positive urothelial cells and
FGF-10 positive fibroblasts. The ensuing estimate is unbiased and free of volume artifacts
commonly present with other counting methods (62). Implementation of the Optical Fractionator
was performed using a BH-2 Olympus microscope equipped with an Optronics DEI 750 digital
video camera and Ludl high precision motorized stage. Data collection and microscope operation
was controlled by Stereo Investigator software (version 3.19, MicroBrightField, Williston,
Vermont).
The application of the fractionator in the present sampling design consisted of initially
systematically collecting every 40th section across the entire bladder starting with a random start
(e.g. a random start might be 12, therefore collect the 12, 52, 92… sections). Hence this set of
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sections (and the structure of interest contained within, i.e., the obstructed bladder) represented
1/40th of the entire structure. Following staining of this set of sections, Ki-67 positive urothelial
cells were counted in a known aerial fraction of the transitional epithelial layer. The aerial fraction
was determined by placing a random stepping grid, generated by the Stereo Investigator software
program, over the section. An appropriate stepping grid (500 x 500 µm, or an area of 250,000 µm2)
was used to place sequential disectors across the surface of the sections. A disector frame (10 x 10 =
100 µm2) was placed in each stepping grid and used to count Ki-67 positive cells according to
optical disector counting rules. Immunopositive cells were readily identified by the dark brown
coloration of the nuclei characteristic of the staining procedures (see Figure 5 in manuscript). The
overlay of this stepping grid was placed randomly (independently) over the transitional epithelium,
thus ensuring that each step was systematic and random. In our experiments, the optical disectors
sampled 1/2500th of the transitional epithelium. Combined with the 1/40th of the structure
represented by the section, the optical disectors sampled 1/100,000th of the entire structure. Cell
counts were summed from all disectors across all sections collected, and the total number was
determined by multiplying the number counted by the inverse of the fraction sampled. Systematic
random sampling has been determined to be fair because every part of the original structure had an
equal probability of being selected due to the random position set within the first interval, and
systematic random sampling offers additional advantages of efficiency (63).
FGF-10 positive cells were counted that were clearly labeled, possessed the characteristic shape
of a fibroblast cell, and did not intercept the top of the tissue section in what was judged to be the
widest cell profile.  Statistical differences between FGF-7 knock-out mice and wild type mice were
determined using Student’s t-test, SPSS base 10 (Mountain View, CA) statistical software.  Tests
for homogeneity of group variance and normal distributions indicated that the non-parametric
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Mann-Whitney test for two-group means comparison was the appropriate statistical test for FGF-10
expression analysis.
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Table 1. Distribution of the Sequence for FGF-7 in the Human Genomea
Chromosome Begin – End of
Genomic Contigb
Accession #
of Contig
Begin – End of
cDNA
% Identity
(Length)
9 310522 - 313542
309333 - 309436
NT_033211.3 834 - 3853
732 -   835
97 (3032)
97 (  105)
9 205822 – 202808c
112194 – 110283c
207019 – 206916c
NT_033210.2 834 -   3853
1941 – 3853
732 - 835
96 (3033)
96 (1921)
97 (  104)
15 4748306 – 4751324
4688024 – 4688581
4687260 – 4687438
4747149 – 4747252
NT_010194.13 834 - 3853
174 -   731
1 -   179
732 -   835
99 (3021)
99 (  558)
100 ( 179)
100 ( 104)
18 60149 – 57146c
61341 – 61238c
NT_024983.8 834 - 3853
732 -   835
95 (3030)
96 (  194)
21 363464 – 366469
362274 - 362377
NT_011512.7 834 - 3824
732 -   835
96 (3029)
97 (  104)
aHuman genome database was queried with the cDNA sequence for bladder FGF-7 and with the NCBI
 reference sequence for the full-length FGF-7 mRNA (RefSeq Accession NM_002009.2). Dotted lines
bracket genomic sequences found with the reference sequence, but not with the bladder sequence           
bunits in kbp; csequence found on minus strand (italicized type).
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      Table 2. Intron / Exon Structure of Human FGF-7 Gene on Chromosome 15
5’ Exon 1 Intron 1 Exon 2 Intron 2 Exon 3 Intron 3 Exon 4
End
Begin
Size
(kbp)
   ? 4687.438
4687.260
   0.179
4688.029
4687.439
   0.591
4688.581
4888.030
   0.552
4747.148
4688.582
  58.567
4747.252
4747.149
   0.104
4748.307
4747.253
   1.055
4751.324
4748.308
   3.017
Seq.
of
Border
acacACGCGC
    ------
AAACAAgtaa
------
acagAAGTCA
    ------
AATTACAgtaa
AsnTyrA
    66
gcagATATC
    snIle
GCAAAGgtat
AlaLys
   101
acagAAAGAA
    LysGlu
       153
        Size = +1 bp to yield inclusive size
        unTn = untranscribed   lower case is intron   upper case is exon
        ---  = untranslated exon
        translated exon has 3-letter amino acid and residue numbering (Figure 4) is underneath
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Table 3.  Distribution of Chromosome 15 FGF-7 Sequences on Other Chromosomesa
Chr 15
(length in
bp)
Chr 18
(length in
bp)
Chr 21
(length in
bp)
Chr 9pt
(length in bp)
Chr 9pm
(length in bp)
Chr 9pc
(length in bp)
Chr 9qc
(length in
bp)
Chr 9qt
(length in bp)
CNSb of Intron
2
47,343,436-
47,354,485
(11,050)
14878089-
14889070
(10.982)
13636398-
13643456
(7,059)
Gap 41146340-
41152725
(6,372)
41867144-
41870812
(3,669) plus
Gap
61209613-
61214951
(5,339)
62207569-
62213939
(6,371)
Exon 3 –
translated
47,354,486-
47,354,589
(104)
14877985-
14878088
(104)
13643457-
13643560
(104)
Gap 41146236-
41146339
(104)
Gap 61214952-
61215055
(104)
62213940-
62214043
(104)
CNS of Intron 3 47,354,590-
47,355,644
(1,055)
14876895-
14877984
(1,090)
13643561-
13644648
(1,088)
Gap 41145149-
41146235
(1,087)
Gap 61215056-
61216150
(1,095)
62214044-
62215130
(1,087)
Exon 4 –
translated
47,355,645-
47,355,839
(195)
14876701-
14876894
(194)
13644649-
13644840
(192)
Gap 41144954-
41145148
(195)
Gap 61216151-
61216346
(196)
62215131-
62215325
(195)
Exon 4 – UTR 47,355,840-
47,358,659
(2,820)
14873895-
14876700
(2,806)
13644841-
13647650
(2,810)
41106274-
41107090
(817) plus
Gap
41142132-
41144953
(2,820)
Gap 61216347-
61219161
(2,815)
62215326-
62218147
(2,822)
CNS of 3’
region
47,358,660-
47,361,636
(2,977)
14870961-
14873894
(2,934)
13647651-
13650563
(2,913)
41107091-
41110060
(2,970)
41139214-
41142131
(2,918)
Gap 61219162-
61220136
(975)
62218148-
62218307
(160) plus
Gap
aSequence Data of the UCSC Genome Browser on April 2003 Freeze
bConserved Non-coding Sequences
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Table 4. Quantification of Urothelial Cell Number by Stereology
Total # urothelial
cells x 106
(mean ± S.E.M.)
Total # Ki67
positive
urothelial cells
x 104
(mean ± S.E.M.)
% Ki-67
positive cells
(mean ± S.E.M.)
Total # fibroblasts
positive for FGF-10
x 103
(mean ± S.E.M.)
WT (n = 8) 0.81 ± 0.13 1.90 ± 1.22 1.78 ± 0.46 0.20 ± 0.06
KO (n = 6) 1.31 ±  0.26 2.02 ± 0.36 1.60 ± 0.94 1.09 ± 0.38
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Figure 1. Duplication of FGF-7 sequences among human chromosomes. The April
2003 version of the Human Genome Database was analyzed for the presence of
chromosome 15 FGF-7 gene elements. Black boxes, coding exons (E3 and E4).
Stippled boxes, 3’ untranslated regions;  White boxes, introns and 3’ flanking
sequences. Chr9pc, FGF-7 copy located proximal to the centromere on the p arm.
Chr9pm, middle copy on the p arm. Chr9pt, copy located proximal to the telomere on
the p arm. Chr9qt, copy located proximal to the telomere on the q arm. Chr9qc, copy
located proximal to the centromere on the q arm.
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Figure 2. Sequence analysis of human urinary bladder FGF-7 and primary
structure of rFGF7-His. The amino acid sequence for rFGF7-His was deduced from
data obtained by the dideoxy sequencing of the PCR-DNA product displayed in Figure
1, lane 2. Residues of rFGF7-His that are not part of the 164 aa wild-type sequence
(uppercase) are represented in lowercase and include the formyl-methionine (residue 1)
and Leu, Glu, and six His residues (residues 166-173). Diamond indicates site of
putative amidation (Gly147). Asterisk indicates site of N-linked glycosylation (Asn16).
Filled circles indicate sites of casein kinase II phosphorylation (Ser18 and Thr150).
Arrow indicates sites of phosphorylation by protein kinase C (Ser124). Underlined
residues represent the FGF family signature (Gly96-Tyr119) (Prosite Database). Bolded
residues represent the glycine box (Asn139-Gly147). Black boxes with white letters
designate residues implicated in the heparin-binding motif (Arg43, Asn117, Asn139,
Gln140, Val145, Lys148, Asn154, Lys155, and Thr156).
1                                                      
mACNDMTPEQ MATNVNCSSP ERHTRSYDYM EGGDIRVRRL FCRTQWYLRI  
51                                                         
DKRGKVKGTQ EMKNNYNIME IRTVAVGIVA IKGVESEFYL AMNKEGKLYA
101                                                 ♦
KKECNEDCNF KELILENHYN TYASAKWTHN GGEMFVALNQ KGIPVRGKKT 
151                       173                            
KKEQKTAHFL PMAITlehhh hhh 
*
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Figure 3. Interaction of rFGF7-His with metal-chelate and heparin affinity
chromatographies. Shown are composite SDS-containing electrophoretic gels stained
with GelCode Blue. Lane 1, elution from Ni-NTA resin with pH 5.3 buffer. Lane 2, elution
from heparin-affinity column with 1.0 M LiCl. Lane 3, 1.0 M elution product from heparin-
affinity resin was applied to a Ni-NTA resin. Shown is the elution of rFGF7-His from the
Ni-NTA resin with pH 5.3 buffer. Lane 4, pH 5.3 elution product from Ni-NTA resin was
applied to a heparin-affinity column. Shown is the elution of rFGF7-His from the heparin-
affinity resin with 1.0 M LiCl.
1          2         3         4
116.0 -
66.2 -
39.2 -
26.6 -
21.3 -
14.4 -
Ni+2 Hep       Hep   Ni+2
Ni+2 Hep  
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Figure 4. Mitogenic activity of rFGF7-His on urothelial cell DNA synthesis. A,
Primary culture of human urothelial cells at confluency (passage 3). Note large
supeficial cell at top of photograph and the round, refractile dividing basal cell at bottom.
B,  Passage 4 bladder urothelial cells were plated at a density of 39,000 cells well-1 of a
96-well plate and grown to confluency in the presence of growth medium. Cultures were
rendered quiescent by incubation for 16 hr in medium that lacked growth stimulators
(“starvation medium”). Increasing concentrations of rFGF7-His were mixed with
starvation medium that contained 0.5 µCi ml-1 [3H]-thymidine  added in a pulse-chase
experiment.
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LUMEN OF 
URINARY 
BLADDER
CAP
Lamina PropriaTE
bv
Figure 5. Induction of murine urothelial cell proliferation by recombinant FGF-7
(Palifermin). rFGF-7 (Palifermin) was administered via intraperitoneal injection each
day for 14 days to C57BL/6J mice. Shown is a section of urinary bladder mucosa that
reacts with immunoglobulins specific for the nuclear antigen Ki-67. Arrows, regions of
urothelium that contain cells positive for Ki-67 (brown nuclei). bv, capillaries.
Counterstained with toluidine blue. 200x.
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Figure 6. Proliferative response of the murine urothelium in response to partial outlet
obstruction. Wild-type or FGF7-null mice (C57BL/6J strain, 8-weeks old) were anesthetized and
the urogenital cavity was opened. A 26 g catheter was inserted into the urethra and up into the
bladder. Silk-thread was tied around the urethra-bladder neck junction. The catheter was
removed and reinserted to verify that partial outlet obstruction would result. After closure of the
cavity, mice were allowed to recover, and housed for 8 additional days. After animals were
euthanized, bladders were removed, fixed, and paraffin-embedded. Sections were cut according
to principles of unbiased stereology, immunostained with antibodies specific for the proliferation
marker Ki-67, and counterstained with Toluidine blue. Quantification of total number of urothelial
cells (A) and total Ki-67 positive urothelial cells (B) was achieved by stereological counting (64).
Reliable estimates of the number of Ki-67 positive proliferating cells contained within the
developing urinary tract was determined by use of the Optical Fractionator (61, 65). wt (wild-
type), ko (knockout or FGF7-null), horizontal bar is mean. Diamond, cell count for an individual
animal that underwent urethral ligation surgery. See Table 4 for corresponding values.
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Figure 7.  Representative disector placement on FGF-10 positive lamina propria
fibroblast cell.   Shown is a representative section from a FGF7-null mouse bladder
immunostained with monoclonal antibodies specific for FGF-10.  Rectangle, disector;  L,
lumen; U, urothelium; LP, lamina propria; MP, muscularis propria. Size bar =     µm.
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SUPPLEMENTAL MATERIALS SECTION
Materials and Methods: Materials
Human urinary bladder cDNA was obtained from Invitrogen (Carlsbad, CA).
Oligonucleotide primers were synthesized by Keystone Laboratories (Foster City, CA).
Escherichia coli strains NovaBlue and BL21trxB(DE3), Perfectly Blunt Cloning Kit, plasmid
pET21d, Bug Buster lysis reagent, and carbenicillin were purchased from Novagen (Madison,
WI). Restriction enzymes NcoI and XhoI, T4 DNA ligase, Taq polymerase, and Complete
Protease Inhibitors were from Roche Molecular Biochemicals (Indianapolis, IN). Ni-NTA metal-
chelate affinity resin was from Qiagen (Chatsworth, CA). HiTrap heparin-sepharose affinity
resins were from Amersham Biochemicals (Piscataway, NJ). SDS-PAGE gels and the Amplified
Alkaline Phosphatase ImmunoBlot Assay detection system were obtained from BioRad
(Hercules, CA). Tetracycline and kanamycin were from Calbiochem (La Jolla, CA).
Recombinant FGF-7 (rFGF-7, Palifermin, rHuKGF)) was provided by Amgen (Thousand Oaks,
CA). Rabbit anti-bovine uroplakin immunoglobulins were obtained from Dr. H. Sun (New York
University, New York, NY).
Methods: Isolation and Dideoxy Sequencing of FGF-7 from Human Urinary Bladder
A population of human bladder cDNAs was used as a template for Taq polymerization. One
pair of oligonucleotide primers was synthesized:  “NcoI”, 5’-
CATCCGGATCCATGGCTTGCAATGACATGACTCCA-3’ and “XhoI”, 5’-
ACTCTCCGGCTACTCGAGAGTTATTGCCATAGGAAG-3’. These primers were designed to
partially anneal to FGF-7 cDNA – the noncomplimentary regions encoded sites for the
restriction endonucleases NcoI and XhoI. Initial PCR conditions employed were 1 cycle at 95 °C
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for 12 min, 30 cycles at 95 °C and 60 °C at 30 s each, 1 cycle at 72 °C for 10 min, and a hold at 4
°C. Subsequent gel electrophoresis indicated a lack of detectable PCR-DNA product. Forty µl of
this reaction product was used as template in a second round of Taq polymerization with the
following thermocycler parameters:  1 cycle at 95 °C for 12 min, 40 cycles at 95 °C and 50 °C
and 72 °C for 1 min each, 1 cycle at 72 °C for 12 min, and a hold at 4 °C. Following gel
electrophoresis, 250 ng of the principal PCR-DNA product at 0.52 kbp was excised from the gel,
recovered by extraction, converted to blunt ends, ligated into pSTBlue-1, and transformed into
competent NovaBlue E. coli. Subsequent growth at 37 °C on agar plates that contained Luria
broth, 50 µg ml-1 carbenicillin, and 15 µg ml-1 kanamycin, resulted in recombinant cultures that
were archived as glycerol stocks and characterized with respect to insert size and dideoxy DNA
sequencing. Clones that were identified as containing correctly oriented and in-frame inserts
were designated pSTBlue-FGF7.
Methods: Cloning into the Bacterial Expression Vector pET21d
Six and one-half µg of pSTBlue-FGF7 were restricted with NcoI and XhoI endonucleases and
electrophoresed through an agarose gel. The DNA of a 0.52 kbp band was excised from the gel,
extracted, and ligated to the expression plasmid pET21d, previously prepared by incubation with
NcoI and XhoI and dephosphorylation with shrimp alkaline phosphatase. After transformation
into BL21trxB(DE3) E. coli, recombinant colonies were generated by growth on Luria broth-agar
plates that contained 50 µg ml-1 carbenicillin, stored as glycerol stocks, and designated pET21d-
FGF7. The resultant open reading frame that included six C-terminal His residues generated a
fusion protein designated as rFGF7-His.
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Methods: Expression, Isolation, and Characterization of Recombinant FGF-7 in E. coli
The insert coding region from pSTBlue1-FGF7 was recloned into the pET21d expression
vector to ultimately form the expression plasmid pET21d-FGF7. The expression of recombinant
FGF-7 (rFGF-7) by transformed E. coli was found to be dependent on the addition of isopropyl-
1-thio-β-D-galactopyranoside, a reagent known to inactivate the lac repressor, thereby permitting
synthesis of FGF-7 mRNA.
Methods: Stereology Procedures
Estimates of the number of total and proliferating (Ki-67 positive) urothelial cells of
obstructed murine bladders were determined by use of the Optical Fractionator (61). The Optical
Fractionator method combines a 3-dimensional unbiased counting frame (the optical disector)
and an unbiased sampling method  (the fractionator) to generate estimates of the total number of
particles of interest, in this case Ki-67 positive urothelial cells. The ensuing estimate is unbiased
and free of volume artifacts commonly present with other counting methods (62).
Implementation of the Optical Fractionator was performed using a BH-2 Olympus microscope
equipped with an Optronics DEI 750 digital video camera and Ludl high precision motorized
stage. Data collection and microscope operation was controlled by Stereo Investigator software
(version 3.19, MicroBrightField, Williston, Vermont).
The application of the fractionator in the present sampling design consisted of initially
systematically collecting every 40th section across the entire bladder starting with a random start
(e.g. a random start might be 12, therefore collect the 12, 52, 92… sections). Hence this set of
sections (and the structure of interest contained within, i.e., the obstructed bladder) represented
1/40th of the entire structure. Following staining of this set of sections, Ki-67 positive urothelial
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cells were counted in a known aerial fraction of the transitional epithelial layer. The aerial
fraction was determined by placing a random stepping grid, generated by the Stereo Investigator
software program, over the section. An appropriate stepping grid (500 x 500 µm, or an area of
250,000 µm2) was used to place sequential disectors across the surface of the sections. A disector
frame (10 x 10 = 100 µm2) was placed in each stepping grid and used to count Ki-67 positive
cells according to optical disector counting rules. Immunopositive cells were readily identified
by the dark brown coloration of the nuclei characteristic of the staining procedures (see Figure 5
in manuscript). The overlay of this stepping grid was placed randomly (independently) over the
transitional epithelium, thus ensuring that each step was systematic and random. In our
experiments, the optical disectors sampled 1/2500th of the transitional epithelium. Combined
with the 1/40th of the structure represented by the section, the optical disectors sampled
1/100,000th of the entire structure. Cell counts were summed from all disectors across all sections
collected, and the total number was determined by multiplying the number counted by the
inverse of the fraction sampled. Systematic random sampling has been determined to be fair
because every part of the original structure had an equal probability of being selected due to the
random position set within the first interval, and systematic random sampling offers additional
advantages of efficiency (63).
Supplemental Figure 1. Agarose gel electrophoresis of human
urinary bladder FGF-7 cDNA.
Lane 1, 100-bp markers are indicated to the left of the figure in
kbp
Lane 2, RT-PCR DNA products encoding FGF-7 from
oligonucleotide primers designed to generate rFGF7-His. Lane
3, RT-PCR DNA products encoding FGF-7 from
oligonucleotide primers designed to generate wild-type rFGF-7.
Shown is a fluorescent image generated by photography of the
gel stained with Sybr Green I. The band at ~525 bp corresponds
to FGF-7 cDNA.
Page 43 of 48
6/9/2008
Results: Isolation and Sequence Analysis of FGF-7 cDNA from Human Urinary Bladder
A partial cDNA fragment that encoded the mature, secreted form of FGF-7 was isolated from
a human urinary bladder cDNA library by reverse transcription (RT) and PCR. Supplemental
Figure 1 demonstrates that the RT-PCR yielded a product that was approximately 0.52 kbp in
size, in agreement with the size predicted from the FGF-7 cDNA cloned from the human
embryonic lung cell line M426 (Accession M60828) (66).
The 0.52 kbp RT-PCR product was subcloned into the high copy vector pSTBlue1 to form
the recombinant plasmid designated pSTBlue1-FGF7. Subsequent dideoxy sequencing of this
0.52 kbp RT-PCR product revealed the presence of a 0.492 kbp bladder sequence. This sequence
was found to be 100% identical with the corresponding region present in the NCBI reference
sequence encoding FGF-7 mRNA (Accession NM_002009.2).
Results: Expression of Recombinant FGF7-His in E. coli
Two types of recombinant (r) FGF-7 were used in this study. rFGF-7 (lacking a C-terminal
His-tag) was prepared and provided by Amgen as the pharmaceutical Palifermin (67). rFGF7-His
was prepared as described below.
A loop of recombinant bacteria from a frozen glycerol stock was streaked on a plate of agar
that contained Media A (Luria broth, 100 µg ml-1 carbenicillin, and 0.2% glucose) and incubated
at 37 °C for 16-24 hr. A 50 ml starter culture in Media A was inoculated with a single colony and
propagated until the optical density at 600 nm reached ∼0.6. After storage of the culture
overnight at 4 °C, cells were recovered by sedimentation at 5000 x g, resuspended in 4 ml of
Media A, and inoculated into 2 L of prewarmed Media A. Once the cultures reached an optical
density at 600 nm of ∼0.6, isopropyl-1-thio-β-D-galactopyranoside was added to a final
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concentration of 1 mM. After 3-4 hrs of continued growth at 37 °C, cells were collected by
sedimentation at 5,000 x g at 4 °C and frozen at –20 °C.
Luria broth used in these experiments contained peptone derived from meat so as to eliminate
lactose that would normally be found in peptone derived from milk. We have found that lactose
in the medium elicits premature activation of the T7lac promoter and of rFGF7-His synthesis.
Isolation of rFGF7-His
Thawed pET21d-FGF7-BL21trxB(DE3) cells were lysed with Bug Buster reagent that
contained additional Complete protease inhibitors. Lysed material was fractionated into soluble
and insoluble fractions by centrifugation at 20,000 x g for 45 min at 4 °C.
 Soluble material was dialyzed overnight at 4 °C versus Buffer A (0.1 M NaH2PO4, 0.3 M
NaCl, and 0.05 M Tris-HCl) (pH 8.0). After clarification of the dialyzate by centrifugation at
20,000 x g for 20 min at 4 °C, imidazole was added to the soluble phase at a final concentration
of 0.025 M. This sample mixture was then applied to a 4 ml column of Ni-NTA resin previously
equilibrated in Buffer A (pH 8.0). The column was developed with Buffer A (pH 8.0) until the
A280 nm < 0.01, with Buffer A (pH 6.0) until the A280 nm < 0.01, with Buffer A (pH 5.3) to elute the
monomeric rFGF7-His protein fraction, and finally with Buffer A (pH 4.5) to elute the
multimeric rFGF7-His protein fraction. Column eluates were monitored at 280 nm by a
Pharmacia Uvicord spectrophotometer connected to analog-to-digital boards of an Intel-based
computer workstation running Rainin Dynamax software.
Alternatively, heparin-affinity chromatography was used to isolate rFGF7-His by the
following procedure. Soluble fractions (above) were dialyzed against 0.05 M Tris-HCl (pH 7.4)
that contained 0.2 M LiCl, and loaded onto a HiTrap Heparin column, equilibrated in the same
Thr –COOH (– His6x)
Heparin-binding region
Supplemental Figure 2. Heparin-
binding region and C-terminal His
hexamer of rFGF7-His is accessible
to the solvent. Shown is a
spacefilling model based on the
published coordinates for the 3.1
angstrom crystal structure of rat FGF-
7 (1) (PDB Accession 1QQK).
Amino acids identified as comprising
a heparin-binding motif are in cyan.
A His tag (His6x) is covalently linked
to the C-terminal Thr140 residue
(green).
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buffer, at 1 ml min-1. After a baseline was established, the column was developed with step
gradients of increasing LiCl concentrations: 0.5 M, 1.0 M, 1.5 M, and 2.0 M. rFGF7-His was
eluted at 1.0 M LiCl.
Results: Distribution and Characterization of FGF-7 Sequences in the Human Genome
Supplemental Figure 3 displays a detailed sequence alignment for the duplicated copies that
have complete sequence information for exons 3 and 4. Of interest was which duplicated copies
retained coding potential. Exon 4 is divided into the coding and noncoding segments at position
12719 (vertical line within the exon 4 box). Frameshift mutations in exon 4 were detected at 2, 2,
and 1 site(s) of the duplicated copies on chromosome 18, 21, and the region proximal to the
centromere of 9q, respectively. Supplemental Figure 3 also includes the sequence alignment at
the junctions of the FGF-7 duplication. The 5' boundaries of the FGF-7 duplicated sequences on
chromosome 18, 21, 9pm, 9qt, and 9qc all appeared to be different except that the sequence
homology of 9pm and 9qt extends beyond the FGF-7 homology. The sequence homology at the
3' ends of chromosome 18, 21, and 9pm also extends beyond the FGF- 7 homology. This
indicates that the FGF-7 duplicated segments on these chromosomes are parts of a larger
duplication unit.
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Supplemental Figure 3. Sequence alignment of exons 3 and 4, and of adjacent regions, of the
FGF-7 gene among human chromosomes. Top line, FGF-7 gene of chromosome 15. Nucleotides
that do not match with the FGF-7 gene of chromosome 15 are in black background. Boxed areas,
exons 3 and 4. Chr9pc, FGF-7 copy located proximal to the centromere on the p arm. Chr9pm,
middle copy on the p arm. Chr9pt, copy located proximal to the telomere on the p arm. Chr9qt,
copy located proximal to the telomere on the q arm. Chr9qc, copy located proximal to the
centromere on the q arm.
Page 47 of 48
6/9/2008
chr15 : ACCGGAAGAAACTTGGAATCCCTCGTGACAGTGAAGTTCTGGATAAGAAAGTGAAAGACATGACAGCACAGGTGTTGTTTTCATTTTTTCTTCTAGTTTT
chr18 : AATTTTTGGCTGTAGCCAACTATAAACCACTTTTTGAAATGAATCAAAGTAAAGCGATATTGTCTATGAATGACAAAAGACAGAATAGCCATGGTTAAAG
      = 1         11        21        31        41        51        61        71        81        91
chr15 : ATCTCATGACTTTAGAAGTGAAAAAAAAAAAAAAGCTGTGAAAGTAAACACCTGGCCATTAACAACAGTGTTGAAAATAAGACTTGTCTTTCTGGCTGTT
chr18 : ACACAATTGACAAGGAAATTTGATTATTTCTATGGCTAACAAAAACCTGTGAATGCCAAGCAACATCCCCTCCACTCTTTCAGTGGTTATTTAGTTATTC
      = 101       111       121       131       141       151       161       171       181       191
chr15 : AGCTTAGAATAACTGAAAAAATAGGCTCCTGGAGTTTTATGTACATTTTATGAAGAACGCATTTGAAGTAAAGTGAAATTGGGGTGCATTAGTTAAGATT
chr18 : AGCTTAGAATAACTGAAAAAATAGGCTCCTGGAGTTTTATGTACATTTTATGAAGAATGCATTTGAAGTAAAATGAAATTGGGGTGCATTAGTTAAGATT
      = 201       211       221       231       241       251       261       271       281       291
After 3,700 bp of intron 2 ...
chr15 : AAGAATTGCTTGATCCTGGGAGGTTCAAGACCCTTGACAATTTGGCCCTAACTCTTTTTCCACCCTCTCACTATTTTGTTACACTTCCTATTCCAGACAT
chr18 : AAGAACTGCTTGAACCTGGGAGGTTCAAGACCCTTGACAATTTGGCCCTGACTCTTTTTCCACCCTCTCACTATTTTGTTACACTTCCTATTCCAGATAT
chr21 : ATATACATGCTTCAGATTCCAGGATTTATGTCATGGGGATGGATCAGGAGTCCTTGAAACCTGGCACTTATTAATAAATGTTGTTTCTAATTTTCTATCA
      = 4001      4011      4021      4031      4041      4051      4061      4071      4081      4091
chr15 : ACAGCTCTAGTTTCAATCTTCTGAACATGACTTTTGAATCTTTGCTTCCATGGCCTTGCACATAGTACTTTTATCTCTCAATTAGCATGTTTCCATCTTT
chr18 : ACAGCTCTAGTTTCAATCTTCTGAACACGACGTTTGAATCTTTGCTTCCATGGCCTTGCACATAGTACTTTTATCTCTCGATTAGCATGTTTCCATCTTT
chr21 : CTGCAAGGTACTCTTATAGACACCATGTGAACATAGTACTTTTATCTCTCTAGCCTTGCACATAGTACTTTTATCTCTCGATTAGCATGTTTCCATCTTT
      = 4101      4111      4121      4131      4141      4151      4161      4171      4181      4191
After 600 bp of intron 2 ...
chr15 : TATTATTAAAGTCAGCTGCATTTAAAAATTAGTAGACTTTGTATTTTAGAACACTTTTAGATTTACAAAAAAAATTGAGCAGATAGGCCAGGCGTGGTGG
chr18 : TATTATTAAAGTCAGCTGCATTTAAAAATTAGTAGAATTTGTATTTTAGAACACTTTTAGATTTAAAAAAATAATTGAGCAGATAGGCCGGGCGCGGTGG
chr21 : TATTATTAAAGTCAGCTGCATTTAAAAATTAGTAGAATTTGTATTTTAGAACACTTTTAGATTTAAAAAAATAATTGAGCAGATAGGCTGGGCATGGTGG
chr9pm: CCACAAATCAAAGAACCTCAGAGAACACCAGATGCTACTATCCTGTCATAAATTAGGTAGTTATTTTATTAAAATAAAAAGATAGGGCCGGGCGCGGTGG
chr9qt: CCACAAATCAAAGAACCTCAGAGAACACCAGATGCTACTATCCTGTCATAAATTAGGTAGTTATTTTATTAAAATAAAAAGATAGGGCCGGGCGCGGTGG
      = 4801      4811      4821      4831      4841      4851      4861      4871      4881      4891
chr15 : CTCACGCCTGTAATCCCAGCACTTTGGGAGGCTGAGGTGGGCAGATCACAAGGTCAGGAGATTGAGACCATCCTGGCTAACACGGTGAAACCTCGTCTCT
chr18 : CTCACCCCTGTAATCCCAGCACTTTGGGAGGCCGAGGTGGGCAGATCACAAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCTCGTCTCT
chr21 : CTCACCCCTGTAATCCCAGCACTTTGGGAGGCCGAGGTGGACAGATCACAAGGTCAGGAGATCAAGACCATCCTGGTTAACACGGTGAAACCTCGTCTCT
chr9pm: CTCACGCCTGTAATCCCAGCACTTTGGGAGGCTGAGGCGGGTGGATCACAAGGTCAGGAGATCGAGGCCATCCTGGCTAACACGGTGAAACCCTGTCTCT
chr9qt: CTCACGCCTGTAATCCCAGCACTTTGGGAGGCTGAGGCGGGTGGATCACAAGGTCAGGAGATCGAGGCCATCCTGGCTAACACGGTGAAACCCTGTCTCT
      = 4901      4911      4921      4931      4941      4951      4961      4971      4981      4991
After 800 bp of intron 2 ...
chr15 : AAAACCTGGGGGCATGACTGCTGGATTATATAGTAAGAGTATGTTTAGTTTTTAAGAAACTGCCAAACTGTCTTCCCATGTGACTGCACCATTTTGCATT
chr18 : AATACCTGGGGGCATGACTGCTGGATTATAT------AGCATATTCAGTTTTTAAGAAACTGCCAAATTGTCTTCCCATGTGACTGCACCATTTTGCATT
chr21 : AATACCTGGGGGCATGACTGCTGGATTATAT------AGCATATTCAGTTTTTAAGAAGCTGCCAAATTGTCTTCCCATGTGACTGCACCATTTTGCATT
chr9pm: AATACCTGGGGGCATGACTGCTGGATTATAT------AGCATGTTTAGTTTTTAAGAAACTGCCAAACTGTCTTCCCATGTGACTGCACCATTTTGCATT
chr9qt: AATACCTGGGGGCATGACTGCTGGATTATAT------AGCATGTTTAGTTTTTAAGAAACTGCCAAACTGTCTTCCCATGTGACTGCACCATTTTGCATT
chr9qc: CAACAGAGTCTTTAGTTGACCATAGAGCTCAGCACAGAGGCCTGCTCAAAGGAGAAGTTTGATATACTTTACATGACTTAAATGATTTTAACTTTGTTGA
      = 5801      5811      5821      5831      5841      5851      5861      5871      5881      5891
chr15 : CCCACTAGTAATGAAAGAGTTTTGGTTGCTTTGCATCCTTGCCAGCATACAGCACTGTTAGTTTTTTGGAGTTTAGTCACGCTAATAGTTGTACAGAGGT
chr18 : CCCACTAGTAATGAAAGAGTTTTGGTTGCTTTGCATCCTTGCCAGCGTACAGCACTGTCAGTTTTCTGGAGTTTAGTCATGCTAATAGTTGTATAGAGGT
chr21 : CCCACTAGTAATGAAAGAATTTTGGTTGCTTTGCATCCTTGCCAGCATACAGCACTGTCAGTTTTTTGGAGTTTAGTCATGCTAATAGTTGTATAGAGGT
chr9pm: CCCACTAGTAATGAAAGAGTTTTGGTTGCTTCGCATCCTTGCCAGCATACAGCACTGTCAGTTTTTTGGAGTTTAGTCATGCTAATAGTTGTATAGAGGT
chr9qt: CCCACTAGTAATGAAAGAGTTTTGGTTGCTTCGCATCCTTGCCAGCATACAGCACTGTCAGTTTTTTGGAGTTTAGTCATGCTAATAGTTGTATAGAGGT
chr9qc: AACTTGTTTAATGAAAGAGTTTTGGTTGCTTTGCATCCTTGCCAGCATACAGCACTGTCAGTTTTTTGGAGTTTAGTCATGCTAATAGTTGTATAGAGGT
      = 5901      5911      5921      5931      5941      5951      5961      5971      5981      5991
After 5,300 bp of intron 2 ...
                                                               EXON 3
chr15 : TTTCTGTGATTCCTTGCAGATATCATGGAAATCAGGACAGTGGCAGTTGGAATTGTGGCAATCAAAGGGGTGGAAAGTGAATTCTATCTTGCAATGAACA
chr18 : TTTCTGTGATTCCTTGAATATATCATGGAAATCAGGACAGTGGCAGTTGGGATTGTGGCAATCAAAGGGGTGGAAAGTGAATTCTATCTTGCAATGAATG
chr21 : TTTCTGTGATTCCTTGCAGATATCATGGAAATCAGGACAGTGGCAGTTGGGATTGTGGCAATCAAAGGGGTGGAAAGTGAATTCTATCTTGCAATGAATG
chr9pm: TTTCTGTGATTCCTTGCAGATATCATGGAAATCAGGACAGTGGCAGTTCGGATTGTGGCAATCAAAGGGGTGGAAAGTGAATTCTATCTTGCAATGAACG
chr9qt: TTTCTGTGATTCCTTGCAGATATCATGGAAATCAGGACAGTGGCAGTTCGGATTGTGGCAATCAAAGGGGTGGAAAGTGAATTCTATCTTGCAATGAACG
chr9qc: TTTCTGTGATTCCTTGCAGATATCATGGAAATCAGGACAGTAGCAGTTGGGATTGTGGCAATCAAAGGGGTGGAAAGTGAATTCTATCTTGCAATGAACG
      = 11301     11311     11321     11331     11341     11351     11361     11371     11381     11391
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                 EXON 3
chr15 : AGGAAGGAAAACTCTATGCAAAGGTATTGATAATTGATAGCTTAGGCTTAATTTTTAAAACTCATTTTTGTCAAAATATCTCACCTTTCTGAAAAGTAAA
chr18 : AGGAAGGAAAACTCTACGCAAAGGTATTGATAATTGATCGCTTAGGCTTAATTTTTAAAACTCATTTTTGTCGAAATATCTCACCATTCTGAAAAGGAAA
chr21 : AGGAAGGAAAACTCTATGCAAAGGTATTGATAATTGATCGCTTAGGCTTAATTTTTAAAACTCATTTTTGTCAAAATATCTCACCATTCTGAAAAGGAAA
chr9pm: AGGAAGGAAAACTCTATGCAAAGGTATTGATAATTGATAGCTTAGGCTTAATTTTTAAAACTCATTTTTGTTGAAATATCTCACCATTCTGAAAAGTAAA
chr9qt: AGGAAGGAAAACTCTATGCAAAGGTATTGATAATTGATAGCTTAGGCTTAATTTTTAAAACTCATTTTTGTTGAAATATCTCACCATTCTGAAAAGTAAA
chr9qc: AGGAAGGAAAACTCTATGCAAAGGTATTGATAATTGATAGCTTAGGCTTAATTTTTAAAACTC--TTTTGTTGAAATATCTCACCATTCTGAAAAGTAAA
      = 11401     11411     11421     11431     11441     11451     11461     11471     11481     11491
After 1,000 bp of intron 3 ...
                                                               EXON 4
chr15 : GTTTGTTTGTTTGTTTTAACAGAAAGAATGCAATGAAGATTGTAACTTCAAAGAACTAATTCTGGAAAACCATTACAACACATATGCATCAGCTAAATGG
chr18 : GTTTGTTTGTTTGTTTTAACAGAAAGAATGCAATGAAGATTGTAACTTCAAAGGACTAATTCTGGAAAACCATTACAACACATATGCCTCAGCTAAATGG
chr21 : GTTTGTTTGTTTGTTTTAACAGAAAGAATGCAATGAAGATTGTAACTTCAAAGGACTAATTCTGGAAAACCATTACAACACATATGCCTCAGCTAAATGG
chr9pm: GTTTGTTTGTTTGTTTGAACAGAAAGAATGCAATGAAGATTGTAACTTCAAAGAACTAATTCTGGAAAACCATTACAACACATATGCAGCAGCTAAATGG
chr9qt: GTTTGTTTGTTTGTTTGAACAGAAAGAATGCAATGAAGATTGTAACTTCAAAGAACTAATTCTGGAAAACCATTACAACACATATGCAGCAGCTAAATGG
chr9qc: GTTTGTTTGTTTGTTTTAACAGAAGGAATGCAATGAAGATTGTAACTTCAAAGATCTAATTCTGGAAAACCATTACAACACATATGCAGCAGCTAAATGG
      = 12501     12511     12521     12531     12541     12551     12561     12571     12581     12591
   EXON 4
chr15 : ACACACAACGGAGGGGAAATGTTTGTTGCCTTAAATCAAAAGGGGATTCCTGTAAGAGG-AAAAAAAACGAAGAAAGAACAAAAAACAGCCCACTTTCTT
chr18 : ACACACAATGGAGGGGAAATGTTTGTTGCCTTAAATCAAAAGGGGATTCCTCTAAGAGG-AAAAAAAATGAAGAAAGAAC-AAAAACAGCCCACTTTCTT
chr21 : ACACACAATGGAGGGGAAATGTTTGTTGCCTTAAATCAAAAGGGGATTCCTGTAAG--G-AAAAAAAATGAAGAAAGAAC-AAAAACAGCCCACTTTGTT
chr9pm: ACACACAATGGAGGGGAAATGTTTGTTGCCTTAAATCAAAAGGGGATTCCTGTAAGAGG-AAAAAAAACGAAGAAAGAACAAAAAACAGCCCACTTTCTT
chr9qt: ACACACAATGGAGGGGAAATGTTTGTTGCCTTAAATCAAAAGGGGATTCCTGTAAGAGG-AAAAAAAACGAAGAAAGAACAAAAAACAGCCCACTTTCTT
chr9qc: ACAAACAACGGAGGGGAAATGTTTGTGGCCTTAAATCAAAAGGGGATTCCTGTAAGAGGAAAAAAAAACAAAGAAAGAACAAAAAACAGCCCACTTTCTT
      = 12601     12611     12621     12631     12641     12651     12661     12671     12681     12691
                       END(of coding)                          EXON 4
chr15 : CCTATGGCAATAACTTAATTGCATATGGTATATAAAGAACCAGTTCCAGCAGGGAGATTTCTTTAAGTGGACTGTTTTCTTTCTTCTCAAAATTTTCTTT
chr18 : CCTATGGCAATAACTTAATTGTATATGGTATATAAAGAACCAGTTCCAGCAGGGAGATTTCTTTAAGTGGACTGT----TTTCTTCTCAAAATTTTCTTT
chr21 : CCTATGGCAATAACTTAATTGCATATGGTATATAAAGAACCAGTTCCAGCAGGGAGATTTCTTTAAGTGGACTGTTTTCTTTCTTCTCAAAATTTTCTTT
chr9pm: CCTATGGCAATAACTTAATTGCATATGGTATATAAAGAACCAGTTCCAGTAGGGAGATTTCTTTAAGTGGACTGTTTTCTTTCTTCTCAAAATTTTCTTT
chr9qt: CCTATGGCAATAACTTAATTGCATATGGTATATAAAGAACCAGTTCCAGTAGGGAGATTTCTTTAAGTGGACTGTTTTCTTTCTTCTCAAAATTTTCTTT
chr9qc: CCTATGGCAATAACTTAATTGCATATGGTATATAAAGAACCAGTTCCAGCAGGGAGATTTCTTTAAGTGGACTGTTTTCTTTCTTCTCAAAATTTTCTTT
      = 12701     12711     12721     12731     12741     12751     12761     12771     12781     12791
After 2,700 bp of 3’ UTR ...
                         EXON 4
chr15 : AAAATGTTCTTTGAAAGATAAAATTAAATACATGAGTTTCTAACAATTAGAAAAGAAAAAATTAAAACATGAAATGATAACAAAAGTAAACAAAAGATAC
chr18 : AAAATGTTCTTTGAAAGATAAAATTAAATACATGAGTTTCTAACAATTAGAAAGGAAAAAATTAAAATATGAAATGATAACAAAAGTAAACAGAAGATAC
chr21 : AAAATGTTATTTGAAAGATAAAATCAAATACATGAGTTTCTAACAATTAGAAAGGAAAAAATTAAAATATGAAATGATAACAAAAGTAAACAGAAGATAC
chr9pm: AAAATGTTCTTTGAAAGATAAAATTAAATACATGAGTTTCTAACAATTAGAAAGGAAAAAATTAAAATATGAAATGATAACAAAAGTAAACAAAAGATAC
chr9qt: AAAATGTTCTTTGAAAGATAAAATTAAATACATGAGTTTCTAACAATTAGAAAGGAAAAAATTAAAATATGAAATGATAACAAAAGTAAACAAAAGATAC
chr9qc: AAAAATTTTCTTTGA----AAGATAAAATACATGAGTTTCTAACAATTAGAAAGGAAAAAATGAAAATATGAA---ATAACAAAAGTAAACAAAAGATAC
      = 15501     15511     15521     15531     15541     15551     15561     15571     15581     15591
After 100 bp ...
chr15 : TACAAATTCAATTTAATGACAGAAGAGAAGGGATGCTGGAGG----TAAATTCTTAGGGTTTCTATCTCATAGAGTTTGCTCTTCTGGTTCTCTAGACTG
chr18 : TACAAATTCAATTTAATGACAGAAGAGAAGGGATGCTGGAGG----TAAATTCTTAGGGTTTCTATCTCATAGAGTTTGCTCTTCTGGTTCTCTAGACTG
chr21 : TACAAATTCAATTTAATGACAGAAGAGAAGGGATGCTGGAGG----TAAATTCTTAGGGTTTCTATCTCATAGAGTTTGCTCTTCTGGTTCTCTAGACTG
chr9pm: TATGAATTCAATTTAATGACAGAAGAGAAGGGATGCTGGAGG----TAAATTCTTAGAGTTTCTATCTCATAGAGTTTGCTCTTCTGATTCTCTAGACTG
chr9qt: TATGAATTCNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
chr9qc: CACAAATTCAATTTAATGAAAGAAGAGAAGGGATGCTGGAGGTAAATAAATTCTTAGAGTTTCTATCTCATAGAGTTTGCTCTTCTGGTTCTCTAGACTG
      = 15701     15711     15721     15731     15741     15751     15761     15771     15781     15791
After 700 bp ...
chr15 : GCTACTCTTTATTCCACTTCTGTACAGTATTTATTCAACCAAGCTGCTGCTTTCAATGAAGGTCACTTGTTCCTTCAGGGACACATATACTCCCACCTAT
chr18 : GCTACTCTTTATTCCACTTCTGTACAGTATTTATTCAACCAAGCTGCTGCTTTCAATGAAGGTCACTTGTTCCTTCAGGGACACATATACTCCCACCTAT
chr21 : GCTACTCTTTATTCCACTTCTGTACAGTATTTATTCAACCAAGCTGCTGCTTTCAGTGAAGGTCACTTGTTCCTTCAGGGACACATATACTCCCACCTAT
chr9pm: GCTACTCTTTATTCCACTTCTGTACAGTATTTATTCAACCAAGCTGCTGCTTTCAATGAAGGTCACTTGTTCCTTCAGGGACACATGTACTCCCACCTAT
chr9qc: GCTACTCTTTATTCCACTTCTATACAGATCATGTCATCTTCAAATAGAGACACTTTCACTTCTTTTCCAATTTGGATGCCTTTTATTTCTTTTTCTTACC
      = 16501     16511     16521     16531     16541     16551     16561     16571     16581     16591
After 1,900 bp ...
chr15 : TGTTTTTGCATCAGAATGATTATGGAATACAAAGTGCACAAAAGTTCTCCCTCCCCCACCACAGTCCATTCTCAAACAGAGCAGCCAAAGTGATTCTGTT
chr18 : TGTTTTTGCATCAGAATGATTATGGAATAGAAAAAAGCATTTCATGCAAATGGACACCAAAAGCGAGCAGCAGTAGCTATTCTCATATGAGACAAAACAA
chr21 : TGTTTTTGCATCAGAATGATTATGGAACAGAAAAGGGCATTTCATGCAAATGGACACCAAAAGCCAGCAGCAGTAGCTATTCTCATATGAGACAAAACAA
chr9pm: TGTTTTTGCATCAGAATGATTATGGAATAGAAAAAGGCATTTCATGCAAATGGACACCAAAAGCGAGCAGCGGTAGCTATTCTCATATGAGACAAAACAA
      = 18501     18511     18521     18531     18541     18551     18561     18571     18581     18591
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